CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 3 enrolled
Drug / intervention
LY2603618 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01296568
NCT01296568Phase 1Completed
CompareCT.gov

Disposition of [14C]LY2603618 Following Intravenous Administration in Patients With Advanced and/or Metastatic Solid Tumors

Eli Lilly and Company·interventional·Posted Feb 15, 2011·Updated Jan 7, 2019

In Brief

A Phase 1 clinical trial evaluating LY2603618, Pemetrexed, and 1 other intervention for Advanced Cancer. Completed, enrolled 3 participants across 1 site.

Detailed Summary

This is an open-label study being conducted to determine the metabolism and physiological disposition of radiolabeled LY2603618 after a single dose in patients with advanced and/or metastatic solid tumors. After a minimum 7-day washout period following the carbon-14-labeled LY2603618 (\[\^14C\]LY2603618) dose, patients will be allowed to continue to receive continued access to LY2603618 in combination with pemetrexed or gemcitabine as outpatients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Cancer
CountriesSwitzerland
Collaborators--

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 15, 2011
Enrollment StartFeb 1, 2011
Primary CompletionDec 1, 2011
Study CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 15.4 years ago

Interventions

LY2603618drug

Administered intravenously

Pemetrexeddrug

Administered intravenously

Gemcitabinedrug

Administered intravenously